NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
NeoGenomics, Inc. (NASDAQ: NEO) to present at the 42nd Annual J.P. Morgan Healthcare Conference
01/02/2024 - 07:05 AM
FT. MYERS, Fla. --(BUSINESS WIRE)--
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced the company will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California .
Members of NeoGenomics’ management team will deliver a presentation followed by Q&A on Monday, January 8th at 5:15 p.m. PT/8:15 p.m. ET. A live and archived audio webcast of the presentation will be available on the “News, Events, and Webcasts” tab via the Investor Relations section of the Company’s website at ir.neogenomics.com .
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help them diagnose and treat cancer. The Company's Advanced Diagnostic Division also serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL , NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida ; Aliso Viejo and San Diego, California ; Research Triangle Park, North Carolina ; and Houston, Texas ; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom . NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States , and pharmaceutical firms in Europe and Asia .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240102990844/en/
Investor Contact
kendra.sweeney@neogenomics.com
Media Contact
lisa.whitmyer@neogenomics.com
Source: NeoGenomics, Inc.
What is the latest announcement from NeoGenomics, Inc. (NASDAQ: NEO)?
NeoGenomics, Inc. (NASDAQ: NEO) will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
When will the presentation take place at the 42nd Annual J.P. Morgan Healthcare Conference?
The presentation by NeoGenomics, Inc. (NASDAQ: NEO) will take place on Monday, January 8th at 5:15 p.m. PT/8:15 p.m. ET.
Where can I access the live and archived webcast of the presentation by NeoGenomics, Inc. (NASDAQ: NEO)?
The live and archived audio webcast of the presentation will be available on the 'News, Events, and Webcasts' tab via the Investor Relations section of the Company’s website at ir.neogenomics.com.
Neogenomics Inc.
NASDAQ:NEO
NEO Rankings
#198 Ranked by Stock Gains
NEO Stock Data
Industry
Testing Laboratories
Sector
Professional, Scientific, and Technical Services
Tags
Health Services, Medical/Nursing Services, Professional, Scientific, and Technical Services, Testing Laboratories
Country
US
City
Fort Myers
About NEO
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
